Coologics

Coologics focuses on developing non-pharmaceutical treatments for vaginal infections. It was founded in Cleveland, US, and has made strategic advancements in its operations.Coologics specializes in a patented, drug-free treatment for vaginal infections, primarily through its flagship product, Vlisse. This innovative solution employs controlled cooling technology to provide faster and more effective relief from symptoms associated with yeast and bacterial infections. Designed as a tampon-like device, Vlisse is intended for immediate symptom relief, significantly reducing the need for traditional antibiotics, which often contribute to antibiotic resistance and prolonged recovery times. The company targets a wide array of end users, including women experiencing recurrent infections, pregnant women at risk of preterm birth, and healthcare providers seeking effective alternatives to traditional treatments.Coologics generates revenue primarily through direct-to-consumer sales of its Vlisse product, alongside partnerships with healthcare providers and potential retail outlets. The transaction structure is designed to facilitate straightforward purchasing options for end-users, ensuring accessibility and convenience. Coologics may implement various pricing strategies, including single purchases and possibly subscription models for ongoing supply needs, providing a flexible purchasing framework for consumers. The emphasis on a clinically proven and patented treatment supports the product's positioning in the market, aligning it with contemporary healthcare demands focused on effective and safe alternatives for vaginal infections. The company plans to expand its market presence beyond North America, targeting additional international regions.

1. Seed

   Apr 23, 2025

   Amount

   $3M

   Investors

   Locked